By Barbara Obstoj-Cardwell. Editor
Notable research news last week included Sarepta Therapeutics reporting another death associated with a trial of its Duchenne muscular dystrophy drug Elevidys. On the M&A front, US pharma major Eli Lilly last Tuesday announced it is to acquire Verve Therapeutics for up to $1.3 billion, along with its VERVE-102. Regulatory news saw the US Food and Drug Administration (FDA) announce a new voucher program aimed at enhancing the health interests of Americans. The FDA also approved Incyte’s Monjuvi for relapsed or refractory follicular lymphoma (LF).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze